Neurologist Dr. Leah Croll talks about the new research suggesting they might help in treating people with alcohol use ...

First-generation GLP-1 weight-loss drugs can help reduce the risk of obesity-related cancers, new research shows. Liraglutide ...

The phase 2 ELAD study of Novo Nordisk's once-daily injectable GLP-1 agonist liraglutide in people with early-stage Alzheimer's has shown that the drug was able to reduce shrinking in the areas of ...

Children who are living with severe obesity are more likely to experience a clinically relevant change in BMI when GLP-1 ...

The diabetes and weight loss drugs are “not cost-effective at their current prices, and are largely unavailable to people with lower incomes,” the report said.

However, it is important to note that the study's cross-sectional design means these findings are correlational, not causal; the data do not show that these factors cause interest in GLP-1 use.

People booze a lot less when taking GLP-1 drugs like Ozempic, a new study out of Ireland ... statistics show. Monkey Business – stock.adobe.com Harmful alcohol use accounts for about 2.6 million ...

Scientists have been studying other possible health benefits of GLP-1s. Popular obesity and diabetes drugs called GLP-1 ... use disorder," Dr. Maurice O'Farrell, lead author of the study and ...

Children who are living with severe obesity are more likely to experience a clinically relevant change in BMI when GLP-1 agonist drugs form part of their treatment, new research being presented at ...

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds over 72 weeks, ...

Ozempic and similar drugs aren’t just for weight loss, more and more research is finding. New data is the latest to show that GLP-1 medications ... for alcohol use disorder, the study ...